LRTM1: A Transmembrane Protein with Potential as A Drug Target and Biomarker

Target Name: LRTM1

NCBI ID: G57408

LRTM1

Other Name(s): Leucine rich repeats and transmembrane domains 1, transcript variant 1 | HT017 | Leucine-rich repeat and transmembrane domain-containing protein 1 | leucine rich repeats and transmembrane domains 1 | Leucine-rich repeat and transmembrane domain-containing protein 1 (isoform 1) | LRTM1_HUMAN | LRTM1 variant 1

LRTM1: A Transmembrane Protein with Potential as A Drug Target and Biomarker

LRTM1 (Leucine rich repeats and transmembrane domains 1, transcript variant 1) is a protein that is expressed in various tissues and cells in the human body. It is characterized by the presence of a unique transmembrane domain and a repeated leucine-rich repeat at its cytoplasmic side.

The transmembrane domain of LRTM1 is a region of the protein that is responsible for its ability to interact with the cell membrane and for its involvement in various cellular processes. This domain has been shown to be involved in the regulation of ion and water transport, as well as in the production of reactive oxygen species.

The repeated leucine-rich repeat of LRTM1 is a conserved region that is found in a variety of proteins and is characterized by the repeated sequence of the amino acid leucine. This repeat is thought to play a role in the stability and localization of the protein.

LRTM1 is a gene that has been implicated in a number of cellular processes, including the regulation of cell growth, the development of cancer, and the regulation of the immune system. It is also thought to be involved in the regulation of the production of neurotransmitters, such as dopamine and serotonin.

As a drug target, LRTM1 is an attractive target for researchers because of its unique transmembrane domain and repeated leucine-rich repeat. These features make it likely to be involved in the regulation of various cellular processes and could provide a useful target for small molecules or other therapeutic agents.

In addition to its potential as a drug target, LRTM1 is also a potential biomarker for a variety of diseases. For example, LRTM1 has been shown to be involved in the regulation of cell growth and has been implicated in the development of cancer. Additionally, LRTM1 has been shown to be involved in the regulation of neurotransmitter production and has been implicated in the development of neurodegenerative diseases.

Overall, LRTM1 is a protein that has significant potential as a drug target and as a biomarker for a variety of diseases. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: Leucine Rich Repeats And Transmembrane Domains 1

The "LRTM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRTM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets